Literature DB >> 21400553

Regulation of hepatic fat and glucose oxidation in rats with lipid-induced hepatic insulin resistance.

Tiago C Alves1, Douglas E Befroy, Richard G Kibbey, Mario Kahn, Roberto Codella, Rui A Carvalho, Kitt Falk Petersen, Gerald I Shulman.   

Abstract

UNLABELLED: Pyruvate dehydrogenase plays a critical role in the regulation of hepatic glucose and fatty acid oxidation; however, surprisingly little is known about its regulation in vivo. In this study we examined the individual effects of insulin and substrate availability on the regulation of pyruvate dehydrogenase flux (V(PDH) ) to tricarboxylic acid flux (V(TCA) ) in livers of awake rats with lipid-induced hepatic insulin resistance. V(PDH) /V(TCA) flux was estimated from the [4-(13) C]glutamate/[3-(13) C]alanine enrichments in liver extracts and assessed under conditions of fasting and during a hyperinsulinemic-euglycemic clamp, whereas the effects of increased plasma glucose concentration on V(PDH) /V(TCA) flux was assessed during a hyperglycemic clamp in conjunction with infusions of somatostatin and insulin to maintain basal concentrations of insulin. The effects of increases in both glucose and insulin on V(PDH) /V(TCA) were examined during a hyperinsulinemic-hyperglycemic clamp. The effects of chronic lipid-induced hepatic insulin resistance on this flux were also examined by performing these measurements in rats fed a high-fat diet for 3 weeks. Using this approach we found that fasting V(PDH) /V(TCA) was reduced by 95% in rats with hepatic insulin resistance (from 17.2 ± 1.5% to 1.3 ± 0.7%, P < 0.00001). Surprisingly, neither hyperinsulinemia per se or hyperglycemia per se were sufficient to increase V(PDH) /V(TCA) flux. Only under conditions of combined hyperglycemia and hyperinsulinemia did V(PDH) /V(TCA) flux increase (44.6 ± 3.2%, P < 0.0001 versus basal) in low-fat fed animals but not in rats with chronic lipid-induced hepatic insulin resistance.
CONCLUSION: These studies demonstrate that the combination of both hyperinsulinemia and hyperglycemia are required to increase V(PDH) /V(TCA) flux in vivo and that this flux is severely diminished in rats with chronic lipid-induced hepatic insulin resistance. 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21400553      PMCID: PMC3077048          DOI: 10.1002/hep.24170

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  22 in total

1.  Control of pyruvate dehydrogenase kinase gene expression.

Authors:  R A Harris; B Huang; P Wu
Journal:  Adv Enzyme Regul       Date:  2001

2.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus.

Authors:  P J RANDLE; P B GARLAND; C N HALES; E A NEWSHOLME
Journal:  Lancet       Date:  1963-04-13       Impact factor: 79.321

Review 3.  Short-term regulation of the mammalian pyruvate dehydrogenase complex.

Authors:  Sławomir Strumiło
Journal:  Acta Biochim Pol       Date:  2005-07-11       Impact factor: 2.149

4.  Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans.

Authors:  K F Petersen; D Laurent; D L Rothman; G W Cline; G I Shulman
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

5.  Mass and positional isotopomer analysis of glucose metabolism in periportal and pericentral hepatocytes.

Authors:  G W Cline; G I Shulman
Journal:  J Biol Chem       Date:  1995-11-24       Impact factor: 5.157

6.  A switch in the direction of the effect of insulin on the partitioning of hepatic fatty acids for the formation of secreted triacylglycerol occurs in vivo, as predicted from studies with perfused livers.

Authors:  S M Rennie; B S Park; V A Zammit
Journal:  Eur J Biochem       Date:  2000-02

7.  Pyruvate dehydrogenase activities and rates of lipogenesis during the fed-to-starved transition in liver and brown adipose tissue of the rat.

Authors:  M J Holness; M C Sugden
Journal:  Biochem J       Date:  1990-05-15       Impact factor: 3.857

8.  Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease.

Authors:  Varman T Samuel; Zhen-Xiang Liu; Amy Wang; Sara A Beddow; John G Geisler; Mario Kahn; Xian-man Zhang; Brett P Monia; Sanjay Bhanot; Gerald I Shulman
Journal:  J Clin Invest       Date:  2007-02-22       Impact factor: 14.808

Review 9.  The pyruvate dehydrogenase complex: nutrient control and the pathogenesis of insulin resistance.

Authors:  M C Sugden; K A Orfali; M J Holness
Journal:  J Nutr       Date:  1995-06       Impact factor: 4.798

10.  Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease.

Authors:  Varman T Samuel; Zhen-Xiang Liu; Xianqin Qu; Benjamin D Elder; Stefan Bilz; Douglas Befroy; Anthony J Romanelli; Gerald I Shulman
Journal:  J Biol Chem       Date:  2004-05-27       Impact factor: 5.157

View more
  21 in total

1.  Thyroid hormone receptor-α gene knockout mice are protected from diet-induced hepatic insulin resistance.

Authors:  François R Jornayvaz; Hui-Young Lee; Michael J Jurczak; Tiago C Alves; Fitsum Guebre-Egziabher; Blas A Guigni; Dongyan Zhang; Varman T Samuel; J Enrique Silva; Gerald I Shulman
Journal:  Endocrinology       Date:  2011-12-06       Impact factor: 4.736

Review 2.  Mechanisms of Insulin Action and Insulin Resistance.

Authors:  Max C Petersen; Gerald I Shulman
Journal:  Physiol Rev       Date:  2018-10-01       Impact factor: 37.312

3.  Hepatic glucose uptake and disposition during short-term high-fat vs. high-fructose feeding.

Authors:  Katie C Coate; Guillaume Kraft; Mary Courtney Moore; Marta S Smith; Christopher Ramnanan; Jose M Irimia; Peter J Roach; Ben Farmer; Doss W Neal; Phil Williams; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-05-27       Impact factor: 4.310

4.  Hepatic hexokinase domain containing 1 (HKDC1) improves whole body glucose tolerance and insulin sensitivity in pregnant mice.

Authors:  Md Wasim Khan; Medha Priyadarshini; Jose Cordoba-Chacon; Thomas C Becker; Brian T Layden
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-12-10       Impact factor: 5.187

5.  Mitochondrial inhibitor as a new class of insulin sensitizer.

Authors:  Yong Zhang; Jianping Ye
Journal:  Acta Pharm Sin B       Date:  2012-08       Impact factor: 11.413

6.  Effect of aging on muscle mitochondrial substrate utilization in humans.

Authors:  Kitt Falk Petersen; Katsutaro Morino; Tiago C Alves; Richard G Kibbey; Sylvie Dufour; Saki Sono; Peter S Yoo; Gary W Cline; Gerald I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-24       Impact factor: 11.205

Review 7.  Hepatic glucose and lipid metabolism.

Authors:  John G Jones
Journal:  Diabetologia       Date:  2016-04-05       Impact factor: 10.122

8.  Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in mice.

Authors:  Andreas L Birkenfeld; Hui-Young Lee; Fitsum Guebre-Egziabher; Tiago C Alves; Michael J Jurczak; Francois R Jornayvaz; Dongyang Zhang; Jennifer J Hsiao; Alejandro Martin-Montalvo; Antje Fischer-Rosinsky; Joachim Spranger; Andreas F Pfeiffer; Jens Jordan; Martin F Fromm; Jörg König; Stefanie Lieske; Christopher M Carmean; David W Frederick; Dirk Weismann; Felix Knauf; Pablo M Irusta; Rafael De Cabo; Stephen L Helfand; Varman T Samuel; Gerald I Shulman
Journal:  Cell Metab       Date:  2011-08-03       Impact factor: 27.287

9.  Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler.

Authors:  Rachel J Perry; Taehan Kim; Xian-Man Zhang; Hui-Young Lee; Dominik Pesta; Violeta B Popov; Dongyan Zhang; Yasmeen Rahimi; Michael J Jurczak; Gary W Cline; David A Spiegel; Gerald I Shulman
Journal:  Cell Metab       Date:  2013-11-05       Impact factor: 27.287

Review 10.  Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes.

Authors:  Andreas L Birkenfeld; Gerald I Shulman
Journal:  Hepatology       Date:  2014-02       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.